Larson Alice A, Giovengo Susan L, Russell Jon I, Michalek Joel E
Graduate Program in Neuroscience, 295 Animal Science/Veterinary Medicine Building, University of Minnesota, 1988 Fitch Avenue, St. Paul, MN 55108, USA Department of Veterinary Pathobiology, University of Minnesota, 1988 Fitch Avenue, Rm 295, St. Paul, MN 55108, USA Department of Medicine/Clinical Immunology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Box 7868, San Antonio, TX 78229-3900, USA University of Texas Health Science Center, University Clinical Research Center, 7434 Louis Pasteur Drive, San Antonio, TX 78229, USA.
Pain. 2000 Aug;87(2):201-211. doi: 10.1016/S0304-3959(00)00284-0.
Substance P (SP), a putative nociceptive transmitter, is increased in the CSF of patients with fibromyalgia syndrome (FMS). Because excitatory amino acids (EAAs) also appear to transmit pain, we hypothesized that CSF EAAs may be similarly involved in this syndrome. We found that the mean concentrations of most amino acids in the CSF did not differ amongst groups of subjects with primary FMS (PFMS), fibromyalgia associated with other conditions (SFMS), other painful conditions not exhibiting fibromyalgia (OTHER) or age-matched, healthy normal controls (HNC). However, in SFMS patients, individual measures of pain intensity, determined using an examination-based measure of pain intensity, the tender point index (TPI), covaried with their respective concentrations of glutamine and asparagine, metabolites of glutamate and aspartate, respectively. This suggests that re-uptake and biotransformation mask pain-related increases in EAAs. Individual concentrations of glycine and taurine also correlated with their respective TPI values in patients with PFMS. While taurine is affected by a variety of excitatory manipulations, glycine is an inhibitory transmitter as well as a positive modulator of the N-methyl-D-asparate (NMDA) receptor. In both PFMS and SFMS patients, TPI covaried with arginine, the precursor to nitric oxide (NO), whose concentrations, in turn, correlated with those of citrulline, a byproduct of NO synthesis. These events predict involvement of NO, a potent signaling molecule thought to be involved in pain processing. Together these metabolic changes that covary with the intensity of pain in patients with FMS may reflect increased EAA release and a positive modulation of NMDA receptors by glycine, perhaps resulting in enhanced synthesis of NO.
P物质(SP)是一种假定的伤害性递质,在纤维肌痛综合征(FMS)患者的脑脊液中含量升高。由于兴奋性氨基酸(EAA)似乎也参与疼痛传递,我们推测脑脊液中的EAA可能同样与该综合征有关。我们发现,原发性纤维肌痛(PFMS)患者、与其他疾病相关的纤维肌痛(SFMS)患者、未表现出纤维肌痛的其他疼痛性疾病(OTHER)患者或年龄匹配的健康正常对照(HNC)组之间,脑脊液中大多数氨基酸的平均浓度没有差异。然而,在SFMS患者中,使用基于检查的疼痛强度测量指标——压痛点指数(TPI)确定的个体疼痛强度测量值,分别与其各自的谷氨酰胺和天冬酰胺浓度相关,谷氨酰胺和天冬酰胺分别是谷氨酸和天冬氨酸的代谢产物。这表明再摄取和生物转化掩盖了与疼痛相关的EAA增加。PFMS患者中甘氨酸和牛磺酸的个体浓度也与其各自的TPI值相关。虽然牛磺酸受多种兴奋性操作的影响,但甘氨酸既是一种抑制性递质,也是N-甲基-D-天冬氨酸(NMDA)受体的正向调节剂。在PFMS和SFMS患者中,TPI均与一氧化氮(NO)的前体精氨酸相关,而精氨酸的浓度又与NO合成的副产物瓜氨酸的浓度相关。这些事件预示着NO的参与,NO是一种被认为参与疼痛处理的强效信号分子。FMS患者中这些与疼痛强度相关的代谢变化可能共同反映了EAA释放增加以及甘氨酸对NMDA受体的正向调节,这可能导致NO合成增加。